BI Asset Management Fondsmaeglerselskab A S Has $41.27 Million Stock Holdings in Zoetis Inc. $ZTS

BI Asset Management Fondsmaeglerselskab A S lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 28.3% during the first quarter, HoldingsChannel reports. The firm owned 349,105 shares of the company’s stock after buying an additional 76,925 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Zoetis were worth $41,268,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in ZTS. Vanguard Group Inc. increased its position in shares of Zoetis by 12.9% in the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after buying an additional 5,474,210 shares in the last quarter. J. Stern & Co. LLP lifted its holdings in Zoetis by 12,431.2% during the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after acquiring an additional 23,877,416 shares in the last quarter. State Street Corp lifted its holdings in Zoetis by 0.8% during the fourth quarter. State Street Corp now owns 19,796,891 shares of the company’s stock worth $2,490,845,000 after acquiring an additional 149,382 shares in the last quarter. Geode Capital Management LLC grew its stake in Zoetis by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock valued at $1,420,294,000 after acquiring an additional 189,235 shares during the period. Finally, Norges Bank bought a new stake in shares of Zoetis in the fourth quarter worth about $734,425,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Trending Headlines about Zoetis

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Multiple law firms, including Rosen, The Gross Law Firm, Kessler Topaz, Bragar Eagel & Squire, and others, announced or reiterated securities class actions against Zoetis, with claims tied to alleged misstatements and omissions about product adoption during the January 14, 2025 to May 6, 2026 period. Article Title
• Negative Sentiment: The lawsuits highlighted a July 27, 2026 lead-plaintiff deadline and suggested investors who bought ZTS during the class period may have suffered losses, increasing legal overhang and uncertainty for the stock. Article Title
• Neutral Sentiment: Zacks noted ZTS recently outperformed the broader market, but that commentary was largely backward-looking and did not change the heavier focus on litigation headlines. Article Title

Insider Buying and Selling at Zoetis

In other Zoetis news, Director Paul Bisaro acquired 2,000 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The stock was bought at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the purchase, the director directly owned 27,862 shares in the company, valued at approximately $2,114,168.56. This represents a 7.73% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Frank A. Damelio acquired 6,650 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The stock was bought at an average price of $75.39 per share, with a total value of $501,343.50. Following the acquisition, the director directly owned 21,458 shares in the company, valued at $1,617,718.62. This represents a 44.91% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders have acquired 11,650 shares of company stock worth $886,384. Insiders own 0.22% of the company’s stock.

Zoetis Trading Down 0.0%

NYSE:ZTS opened at $78.69 on Friday. Zoetis Inc. has a twelve month low of $72.38 and a twelve month high of $161.77. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The business has a 50 day moving average price of $93.01 and a two-hundred day moving average price of $112.54. The company has a market cap of $32.99 billion, a P/E ratio of 13.05, a price-to-earnings-growth ratio of 1.23 and a beta of 0.75.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. During the same period in the prior year, the business earned $1.48 earnings per share. Zoetis’s revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, analysts expect that Zoetis Inc. will post 6.88 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be given a $0.53 dividend. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.7%. Zoetis’s dividend payout ratio (DPR) is 35.16%.

Analysts Set New Price Targets

A number of research firms have recently commented on ZTS. Stifel Nicolaus dropped their price target on Zoetis from $105.00 to $95.00 and set a “hold” rating on the stock in a research report on Friday, May 22nd. Morgan Stanley reissued an “overweight” rating and set a $115.00 target price on shares of Zoetis in a research note on Friday, May 15th. Citigroup dropped their target price on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Six analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Zoetis currently has a consensus rating of “Hold” and an average target price of $133.92.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.